{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:17:39Z","timestamp":1791289059986,"version":"4.3.0"},"reference-count":47,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,8,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Mantle cell lymphoma (MCL) is characterized by a t(11;14) resulting in overexpression of cyclin D1 messenger RNA. This study tested whether temsirolimus (previously known as CCI-779), an inhibitor of the mammalian target of rapamycin kinase that regulates cyclin D1 translation, could produce tumor responses in patients with MCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Patients with relapsed or refractory MCL were eligible to receive temsirolimus 250 mg intravenously every week as a single agent. Patients with a tumor response after six cycles were eligible to continue drug for a total of 12 cycles or two cycles after complete remission, and were then observed without maintenance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty-five patients were enrolled and were assessable for toxicity; one patient had MCL by histology but was cyclin D1 negative and was ineligible for efficacy. The median age was 70 years (range, 38 to 89 years), 91% were stage 4, and 69% had two or more extranodal sites. Patients had received a median of three prior therapies (range, one to 11), and 54% were refractory to the last treatment. The overall response rate was 38% (13 of 34 patients; 90% CI, 24% to 54%) with one complete response (3%) and 12 partial responses (35%). The median time-to-progression in all patients was 6.5 months (95% CI, 2.9 to 8.3 months), and the duration of response for the 13 responders was 6.9 months (95% CI, 5.2 to 12.4 months). Hematologic toxicities were the most common, with 71% (25 of 35 patients) having grade 3 and 11% (four of 35 patients) having grade 4 toxicities observed. Thrombocytopenia was the most frequent cause of dose reductions but was of short duration, typically resolving within 1 week.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Single-agent temsirolimus has substantial antitumor activity in relapsed MCL. This study demonstrates that agents that selectively target cellular pathways dysregulated in MCL cells can produce therapeutic benefit. Further studies of this agent in MCL and other lymphoid malignancies are warranted.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.13.466","type":"journal-article","created":{"date-parts":[[2005,6,28]],"date-time":"2005-06-28T00:34:57Z","timestamp":1119918897000},"page":"5347-5356","source":"Crossref","is-referenced-by-count":434,"title":["Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma"],"prefix":"10.1200","volume":"23","author":[{"given":"Thomas E.","family":"Witzig","sequence":"first","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; Scottsdale CCOP, Scottsdale, AZ; Carle Cancer Center CCOP, Urbana, IL; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Wichita Community Clinical Oncology Program, Wichita, KS; and Hematology & Oncology of Dayton Inc, Dayton, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Geyer","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; Scottsdale CCOP, Scottsdale, AZ; Carle Cancer Center CCOP, Urbana, IL; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Wichita Community Clinical Oncology Program, Wichita, KS; and Hematology & Oncology of Dayton Inc, Dayton, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; Scottsdale CCOP, Scottsdale, AZ; Carle Cancer Center CCOP, Urbana, IL; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Wichita Community Clinical Oncology Program, Wichita, KS; and Hematology & Oncology of Dayton Inc, Dayton, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Inwards","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; Scottsdale CCOP, Scottsdale, AZ; Carle Cancer Center CCOP, Urbana, IL; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Wichita Community Clinical Oncology Program, Wichita, KS; and Hematology & Oncology of Dayton Inc, Dayton, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; Scottsdale CCOP, Scottsdale, AZ; Carle Cancer Center CCOP, Urbana, IL; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Wichita Community Clinical Oncology Program, Wichita, KS; and Hematology & Oncology of Dayton Inc, Dayton, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kurtin","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; Scottsdale CCOP, Scottsdale, AZ; Carle Cancer Center CCOP, Urbana, IL; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Wichita Community Clinical Oncology Program, Wichita, KS; and Hematology & Oncology of Dayton Inc, Dayton, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; Scottsdale CCOP, Scottsdale, AZ; Carle Cancer Center CCOP, Urbana, IL; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Wichita Community Clinical Oncology Program, Wichita, KS; and Hematology & Oncology of Dayton Inc, Dayton, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Luyun","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; Scottsdale CCOP, Scottsdale, AZ; Carle Cancer Center CCOP, Urbana, IL; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Wichita Community Clinical Oncology Program, Wichita, KS; and Hematology & Oncology of Dayton Inc, Dayton, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Flynn","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; Scottsdale CCOP, Scottsdale, AZ; Carle Cancer Center CCOP, Urbana, IL; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Wichita Community Clinical Oncology Program, Wichita, KS; and Hematology & Oncology of Dayton Inc, Dayton, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roscoe F.","family":"Morton","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; Scottsdale CCOP, Scottsdale, AZ; Carle Cancer Center CCOP, Urbana, IL; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Wichita Community Clinical Oncology Program, Wichita, KS; and Hematology & Oncology of Dayton Inc, Dayton, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaker R.","family":"Dakhil","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; Scottsdale CCOP, Scottsdale, AZ; Carle Cancer Center CCOP, Urbana, IL; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Wichita Community Clinical Oncology Program, Wichita, KS; and Hematology & Oncology of Dayton Inc, Dayton, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Gross","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; Scottsdale CCOP, Scottsdale, AZ; Carle Cancer Center CCOP, Urbana, IL; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Wichita Community Clinical Oncology Program, Wichita, KS; and Hematology & Oncology of Dayton Inc, Dayton, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; Scottsdale CCOP, Scottsdale, AZ; Carle Cancer Center CCOP, Urbana, IL; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Wichita Community Clinical Oncology Program, Wichita, KS; and Hematology & Oncology of Dayton Inc, Dayton, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"BIB1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04761.x"},{"key":"BIB2","doi-asserted-by":"publisher","DOI":"10.1097\/00125480-199811000-00011"},{"key":"BIB3","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/112.3.319"},{"key":"BIB4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701046"},{"key":"BIB5","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z"},{"key":"BIB6","unstructured":"Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927,1998-1932,"},{"key":"BIB7","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709050890"},{"key":"BIB8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.579"},{"key":"BIB9","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008251301319"},{"key":"BIB10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/11.suppl_1.S117"},{"key":"BIB11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"BIB12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.13"},{"key":"BIB13","doi-asserted-by":"crossref","unstructured":"Ghielmini M, Schmitz SF, Burki K, et al: The effect of Rituximab on patients with follicular and mantle-cell lymphoma: Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 11:123,2000-126,","DOI":"10.1093\/annonc\/11.suppl_1.S123"},{"key":"BIB14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3158"},{"key":"BIB15","unstructured":"Inwards D, Brown D, Fonseca R, et al: NCCTG phase II trial of 2-chlorodeoxyadenosine (2-CDA) as initial therapy for mantle cell lymphoma: A well-tolerated treatment with promising activity. Blood 94:660a,1999, (suppl 1)"},{"key":"BIB16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1288"},{"key":"BIB17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"BIB18","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1212704"},{"key":"BIB19","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1362"},{"key":"BIB20","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5322.99"},{"key":"BIB21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.4.1432"},{"key":"BIB22","doi-asserted-by":"publisher","DOI":"10.1101\/gad.887201"},{"key":"BIB23","doi-asserted-by":"publisher","DOI":"10.1101\/gad.13.11.1422"},{"key":"BIB24","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00117-3"},{"key":"BIB25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M202014200"},{"key":"BIB26","doi-asserted-by":"publisher","DOI":"10.1038\/nrc839"},{"key":"BIB27","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4892(03)00071-7"},{"key":"BIB28","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(02)00051-5"},{"key":"BIB29","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2003.n.018"},{"key":"BIB30","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000108100.53239.b7"},{"key":"BIB31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.918"},{"key":"BIB32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"BIB33","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"BIB34","unstructured":"Meeker TC, Sellers W, Harvey R, et al: Cloning of the t(11;14)(q13;q32) translocation breakpoints from two human leukemia cell lines. Leukemia 5:733,1991-737,"},{"key":"BIB35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2098"},{"key":"BIB36","doi-asserted-by":"publisher","DOI":"10.1006\/abio.2001.5313"},{"key":"BIB37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.171076798"},{"key":"BIB38","unstructured":"Peralba JM, DeGraffenried L, Friedrichs W, et al: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887,2003-2892,"},{"key":"BIB39","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200403000-00004"},{"key":"BIB40","unstructured":"Lefrere F, Delmer A, Levy V, et al: Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: An update of a prospective study. Haematologica 89:1275,2004-1276,"},{"key":"BIB41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.116"},{"key":"BIB42","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(03)00180-1"},{"key":"BIB43","doi-asserted-by":"publisher","DOI":"10.1038\/nm1052"},{"key":"BIB44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.185"},{"key":"BIB45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.164"},{"key":"BIB46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"BIB47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.13.466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:09:39Z","timestamp":1735776579000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.13.466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,10]]},"references-count":47,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2005,8,10]]}},"alternative-id":["10.1200\/JCO.2005.13.466"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.13.466","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,10]]}}}